0000835887-15-000047.txt : 20150611 0000835887-15-000047.hdr.sgml : 20150611 20150611135717 ACCESSION NUMBER: 0000835887-15-000047 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150603 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20150611 DATE AS OF CHANGE: 20150611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROGENICS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000835887 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133379479 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23143 FILM NUMBER: 15925538 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9147892800 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 8-K 1 form8_k10jun2015.htm FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) June 10, 2015
 
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
  
000-23143
  
13-3379479
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)
         
777 Old Saw Mill River Road, Tarrytown, New York
  
10591
(Address of principal executive offices)
  
(Zip Code)
Registrant's telephone number, including area code (914) 789-2800
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Item 5.07.
Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, stockholders voted on (i) the election of directors; (ii) an advisory vote on the compensation of the Company's named executive officers, (iii) ratification of the Board of Directors' selection of Ernst & Young LLP as the Company's independent registered public accounting firm for 2015. The number of votes cast for and against, and abstentions and broker non-votes with respect to each matter are set forth below.
 
 
 
For
 
Against
 
Abstain
 
Broker Non-Votes
 1.  Election of Directors
 
 
 
 
 
 
 
 15,013,359
  Peter J. Crowley
 
43,318,589
 
2,403,726
 
330,712
 
 
  Paul J. Maddon
 
44,675,056
  
1,048,675
  
329,296
 
 
  Mark R. Baker
 
44,678,211
  
1,045,363
  
329,453
 
 
  Karen J. Ferrante
 
45,328,185
  
394,164
  
330,678
 
 
  Michael D. Kishbauch
 
44,099,534
  
1,622,357
  
331,136
 
 
  David A. Scheinberg
 
44,958,936
  
764,863
  
329,228
 
 
  Nicole S. Williams
 
45,238,637
  
484,487
  
329,903
 
 
 
 
 
 
 
 
 
 
 
2.  Advisory vote on compensation of named executive officers
 
45,492,566
  
207,659
  
352,802
 
15,013,359
 
 
          
 
 
3.  Ratification of selection of Ernst & Young LLP
 
60,596,087
  
123,031
  
347,268
 
-
 
 
 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
PROGENICS PHARMACEUTICALS, INC.
 
By:
/s/ ANGELO W. LOVALLO, JR.
   
Angelo W. Lovallo, Jr.
   
Vice President - Finance & Treasurer
   
(Principal Financial and Accounting Officer)

 
 
Date: June 11, 2015